Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2017
A Mysterious Role of Arginine Vasopressin Levels in Ménière's Disease-Meta-analysis of Clinical Studies.
СтатьяМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Jing, Zhou Jie, Dong Lu, Fan Wenjing, Zhang Jinyu, Wu Caiqin
Аннотация
OBJECTIVE: There are contradicting claims that patients with Ménière's disease (MD) have elevated levels of arginine vasopressin (AVP). The results of published studies regarding the difference of AVP level between MD patients and non-MD control subjects are inconsistent. We propose that the discrepancy of AVP levels during different MD phases may be a potential reason. Thus, we conducted a meta-analysis to analyze the precise estimate of this hypothesis.
DATA SOURCES: PubMed, Medline, and Cochrane databases from the earliest publication, up until September 2016; references from meta-analyses and related review articles.
STUDY SELECTION AND DATA EXTRACTION: Clinical studies that reported AVP level in MD patients and non-MD controls were independently reviewed according to the inclusion criteria. The Newcastle-Ottawa Scale was used to assess quality of studies.
DATA SYNTHESIS: Random effects model was used to calculate the weighted mean difference.
CONCLUSION: Eight studies met the inclusion criteria. AVP levels of MD patients in acute phase (WMD = 2.29, 95% CI = 0.84-3.74, Z = 3.10, p = 0.002) were significantly higher than non-MD subjects. For MD patients in remission phase the difference of AVP levels between the MD patients and the non-MD controls was found (WMD = 0.54, 95% CI = -0.06 to 1.02, Z = 2.20, p = 0.03). However, AVP level was not an ideal biomarker of MD patients. Regardless of MD phase, there were no significant differences in the AVP level of MD patients (WMD = 0.27, 95% CI = -0.10 to 0.64, Z = 1.43, p = 0.15). Future investigations with larger sample sizes are needed to verify the results.
DATA SOURCES: PubMed, Medline, and Cochrane databases from the earliest publication, up until September 2016; references from meta-analyses and related review articles.
STUDY SELECTION AND DATA EXTRACTION: Clinical studies that reported AVP level in MD patients and non-MD controls were independently reviewed according to the inclusion criteria. The Newcastle-Ottawa Scale was used to assess quality of studies.
DATA SYNTHESIS: Random effects model was used to calculate the weighted mean difference.
CONCLUSION: Eight studies met the inclusion criteria. AVP levels of MD patients in acute phase (WMD = 2.29, 95% CI = 0.84-3.74, Z = 3.10, p = 0.002) were significantly higher than non-MD subjects. For MD patients in remission phase the difference of AVP levels between the MD patients and the non-MD controls was found (WMD = 0.54, 95% CI = -0.06 to 1.02, Z = 2.20, p = 0.03). However, AVP level was not an ideal biomarker of MD patients. Regardless of MD phase, there were no significant differences in the AVP level of MD patients (WMD = 0.27, 95% CI = -0.10 to 0.64, Z = 1.43, p = 0.15). Future investigations with larger sample sizes are needed to verify the results.